FEASIBILITY TRADE-OFFS IN DECARBONISING THE POWER SECTOR WITH HIGH COAL DEPENDENCE: THE CASE OF KOREA


A systematic review of the safety of tirzepatide-a new dual GLP1 and GIP agonist - is its safety profile acceptable?

AimsTirzepatide is a novel dual glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 receptor agonist (GLP-1 RA).At present, there is no controversy over its effectiveness, but its safety.We conducted a systematic review to assess the safety of tirzepatide.MethodsWe searched PubMed, Embase and Cochrane databases for randomized

read more